Nivolumab/hyaluronidase
Nivolumab and hyaluronidase-nvhy (Opdivo Qvantig) for subcutaneous injection is a combination agent with nivolumab, an anti-programmed death receptor-1 (PD-1) monoclonal antibody, and hyaluronidase, an endoglycosidase. The addition of the hyaluronidase allows the primary active agent, nivolumab, to be administered as a subcutaneous injection. This is different from nivolumab, which is typically administered intravenously.
Nivolumab and hyaluronidase-nvhy is indicated as treatment for various cancer types including:
- Colon cancer
- Esophageal cancer
- Gastric cancer
- Head and Neck
- Hepatocellular carcinoma:
- Melanoma
- Non-small cell lung cancer
- Renal cell carcinoma
- Urothelial carcinoma
Provider Resource
